We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STERIS posted adjusted EPS of $2.59, up 10.7%, while revenues rose 7.3% to $1.49 billion.
STE's Healthcare, AST and Life Sciences all grew, while adjusted operating margin expanded 99 bps to 23.8%.
STERIS reaffirmed fiscal 2027 revenue growth of 7-8% and adjusted EPS guidance of $11.10-$11.30.
STERIS plc (STE - Free Report) reported first-quarter fiscal 2027 adjusted earnings of $2.59 per share, up 10.7% year over year. The bottom line beat the Zacks Consensus Estimate by 1.97%, supported by higher volume, pricing, productivity and a favorable business mix.
On a GAAP basis, earnings per share (EPS) were $2.04 compared with $1.79 cents in the prior-year quarter.
Revenues rose 7.3% to $1.49 billion but missed the consensus mark by 0.83%. Constant-currency organic revenues increased 6.2%, while total backlog advanced 7.7% year over year to $553.9 million.
Following the earnings announcement, STE stock fell 2.4% in after-market trading yesterday. The decline was likely due to investor concerns over the company’s modest top-line miss.
STERIS Posts Broad Segment Gains
Healthcare revenues increased 7.6% to $1.05 billion. Service revenues grew 9.6%, consumables revenues advanced 9.2% and capital equipment revenues rose 1.4%. Constant-currency organic growth was 6.4%. Healthcare operating income increased 10.5% to $260.2 million. The improvement reflected higher volume, pricing, productivity and favorable mix, partly offset by inflation and increased tariff costs. The segment’s backlog rose 10% to $444 million.
AST revenues rose 5.8% to $297.6 million, driven by 6% service growth despite a 13% decline in capital equipment revenues. Segment operating income increased 4.5% to $142.9 million, as improved pricing was partly offset by higher depreciation and labor costs.
Life Sciences revenues climbed 8.6% to $146.7 million. Capital equipment revenues rose 17%, consumables increased 8% and service revenues grew 2%. Operating income advanced 5.3% to $61.8 million, aided by improved pricing and volume but restrained by inflation and lower productivity.
STE Expands Adjusted Profitability
Gross profit increased to $684.2 million from $628 million in the prior-year quarter. Gross margin expanded 69 basis points (bps) year over year to 45.8%, despite a 6% increase in cost of revenues.
Selling, general and administrative expenses increased 4.5% to $369.7 million, while research and development expenses rose 8.3% to $28.6 million. Total operating expenses increased 4.3% to $398.3 million. Adjusted income from operations advanced 12% to $354.8 million and the adjusted operating margin expanded 99 bps to 23.8%.
STERIS Builds Cash and Financial Flexibility
Cash and cash equivalents increased to $482.3 million as of June 30, 2026, from $439.6 million as of March 31, 2026. Long-term indebtedness declined to $1.65 billion from $1.81 billion.
Cumulative cash flow from operating activities totaled $367.1 million compared with $420 million a year ago. The company also repurchased $115.5 million of ordinary shares and paid $61.4 million in dividends during the quarter.
STE Reaffirms Fiscal 2027 Outlook
STERIS reiterated fiscal 2027 as-reported revenue growth guidance of 7-8%. Constant-currency organic revenue growth is still expected in the range of 6-7%. The Zacks Consensus Estimate is pegged at $6.37 billion, implying 7.4% growth from fiscal 2025.
Adjusted earnings per share are projected to be between $11.10 and $11.30. The Zacks Consensus Estimate for the metric is pegged at $11.17.
Our Take
STERIS ended first-quarter fiscal 2027 with mixed results, with earnings beating estimates but revenues missing the same. However, the expansion of both the margins looks encouraging.
The quarter reflected stable demand across its Healthcare segment. Share gains in consumables and services have fueled the performance, underpinned by solid order growth for capital equipment. Meanwhile, management flagged tariffs and inflation as notable offsets.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.
DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.
Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.
MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.
View the Zacks #1 Rank List
Image: Bigstock
STE Q1 Earnings Beat, Revenues Miss, Stock Dips in Aftermarket Trading
Key Takeaways
STERIS plc (STE - Free Report) reported first-quarter fiscal 2027 adjusted earnings of $2.59 per share, up 10.7% year over year. The bottom line beat the Zacks Consensus Estimate by 1.97%, supported by higher volume, pricing, productivity and a favorable business mix.
On a GAAP basis, earnings per share (EPS) were $2.04 compared with $1.79 cents in the prior-year quarter.
Revenues rose 7.3% to $1.49 billion but missed the consensus mark by 0.83%. Constant-currency organic revenues increased 6.2%, while total backlog advanced 7.7% year over year to $553.9 million.
Following the earnings announcement, STE stock fell 2.4% in after-market trading yesterday. The decline was likely due to investor concerns over the company’s modest top-line miss.
STERIS Posts Broad Segment Gains
Healthcare revenues increased 7.6% to $1.05 billion. Service revenues grew 9.6%, consumables revenues advanced 9.2% and capital equipment revenues rose 1.4%. Constant-currency organic growth was 6.4%. Healthcare operating income increased 10.5% to $260.2 million. The improvement reflected higher volume, pricing, productivity and favorable mix, partly offset by inflation and increased tariff costs. The segment’s backlog rose 10% to $444 million.
AST revenues rose 5.8% to $297.6 million, driven by 6% service growth despite a 13% decline in capital equipment revenues. Segment operating income increased 4.5% to $142.9 million, as improved pricing was partly offset by higher depreciation and labor costs.
Life Sciences revenues climbed 8.6% to $146.7 million. Capital equipment revenues rose 17%, consumables increased 8% and service revenues grew 2%. Operating income advanced 5.3% to $61.8 million, aided by improved pricing and volume but restrained by inflation and lower productivity.
STE Expands Adjusted Profitability
Gross profit increased to $684.2 million from $628 million in the prior-year quarter. Gross margin expanded 69 basis points (bps) year over year to 45.8%, despite a 6% increase in cost of revenues.
Selling, general and administrative expenses increased 4.5% to $369.7 million, while research and development expenses rose 8.3% to $28.6 million. Total operating expenses increased 4.3% to $398.3 million. Adjusted income from operations advanced 12% to $354.8 million and the adjusted operating margin expanded 99 bps to 23.8%.
STERIS Builds Cash and Financial Flexibility
Cash and cash equivalents increased to $482.3 million as of June 30, 2026, from $439.6 million as of March 31, 2026. Long-term indebtedness declined to $1.65 billion from $1.81 billion.
STERIS plc Price, Consensus and EPS Surprise
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
Cumulative cash flow from operating activities totaled $367.1 million compared with $420 million a year ago. The company also repurchased $115.5 million of ordinary shares and paid $61.4 million in dividends during the quarter.
STE Reaffirms Fiscal 2027 Outlook
STERIS reiterated fiscal 2027 as-reported revenue growth guidance of 7-8%. Constant-currency organic revenue growth is still expected in the range of 6-7%. The Zacks Consensus Estimate is pegged at $6.37 billion, implying 7.4% growth from fiscal 2025.
Adjusted earnings per share are projected to be between $11.10 and $11.30. The Zacks Consensus Estimate for the metric is pegged at $11.17.
Our Take
STERIS ended first-quarter fiscal 2027 with mixed results, with earnings beating estimates but revenues missing the same. However, the expansion of both the margins looks encouraging.
The quarter reflected stable demand across its Healthcare segment. Share gains in consumables and services have fueled the performance, underpinned by solid order growth for capital equipment. Meanwhile, management flagged tariffs and inflation as notable offsets.
STE’s Zacks Rank & Key Picks
STE currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Quest Diagnostics (DGX - Free Report) and Medpace (MEDP - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Quest Diagnostics, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $3.12, which outpaced the Zacks Consensus Estimate by 11%. Revenues of $3.04 billion topped the Zacks Consensus Estimate by 2.1%.
DGX has an earnings yield of 4.7%, almost in line with the industry’s yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.77%.
Medpace, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $4.25, which beat the Zacks Consensus Estimate by 4.17%. Revenues of $707.3 million outperformed the consensus mark by 1.12%.
MEDP has a historical five-year earnings growth rate of 30.5% compared with the industry’s 5.6% growth. In the trailing four quarters, the company delivered an average earnings beat of 10.16%.